|
2025-03-07 |
2025-03-05 |
V
Verkauf
|
Clark James David
SVP, Cont & Chief Acct Officer
Führungsperson
|
7.513
-47.2%
66,35
498.488 USD
|
7.513
-47.2%
|
66,35
|
498.488 USD
|
|
|
2025-02-19 |
2025-02-18 |
K
Kauf
|
Mahoney Michael F
Nicht geschäftsführender Verwaltungsratsmitglied
|
30.000
+320.6%
66,70
2.001.000 USD
|
30.000
+320.6%
|
66,70
|
2.001.000 USD
|
|
|
2024-05-02 |
2024-05-02 |
K
Kauf
|
LUDWIG EDWARD J
Nicht geschäftsführender Verwaltungsratsmitglied
|
1.000
+4.8%
53,88
53.879 USD
|
1.000
+4.8%
|
53,88
|
53.879 USD
|
|
|
2024-05-02 |
2024-05-02 |
K
Kauf
|
Mahoney Michael F
Nicht geschäftsführender Verwaltungsratsmitglied
|
9.181
+5246.3%
54,49
500.294 USD
|
9.181
+5246.3%
|
54,49
|
500.294 USD
|
|
|
2024-02-16 |
2024-02-16 |
V
Verkauf
|
Shah Prem S
EVP and Pres-Pharm, Consumer W
Führungsperson
|
29.473
-42.6%
76,95
2.267.947 USD
|
29.473
-42.6%
|
76,95
|
2.267.947 USD
|
|
|
2023-11-06 |
2023-11-03 |
K
Kauf
|
LUDWIG EDWARD J
Nicht geschäftsführender Verwaltungsratsmitglied
|
2.000
+10.7%
70,47
140.930 USD
|
2.000
+10.7%
|
70,47
|
140.930 USD
|
|
|
2023-08-04 |
2023-08-03 |
V
Verkauf
|
Clark James David
SVP, Cont & Chief Acct Officer
Führungsperson
|
23.128
-83.1%
74,94
1.733.212 USD
|
23.128
-83.1%
|
74,94
|
1.733.212 USD
|
|
|
2023-08-04 |
2023-08-03 |
V
Verkauf
|
Clark James David
SVP, Cont & Chief Acct Officer
Führungsperson
|
2.631
-8.6%
74,79
196.792 USD
|
2.631
-8.6%
|
74,79
|
196.792 USD
|
|
|
2023-05-05 |
2023-05-03 |
K
Kauf
|
Lynch Karen S
President and CEO
Geschäftsführender Verwaltungsratsmitglied
|
14.000
+3.4%
69,75
976.567 USD
|
14.000
+3.4%
|
69,75
|
976.567 USD
|
|
|
2022-12-16 |
2022-12-15 |
GV
Geplanter Verkauf
|
Moriarty Thomas M
EVP & General Counsel
Führungsperson
|
36.490
-5.7%
98,24
3.584.869 USD
|
36.490
-5.7%
|
98,24
|
3.584.869 USD
|
|
|
2022-12-16 |
2022-12-15 |
GV
Geplanter Verkauf
|
Moriarty Thomas M
EVP & General Counsel
Führungsperson
|
100.976
-14.2%
98,40
9.936.311 USD
|
100.976
-14.2%
|
98,40
|
9.936.311 USD
|
|
|
2022-08-05 |
2022-08-04 |
GV
Geplanter Verkauf
|
Lotvin Alan
EVP&President-PharmacyServices
Führungsperson
|
22.541
-17.1%
104,00
2.344.264 USD
|
22.541
-17.1%
|
104,00
|
2.344.264 USD
|
|
|
2022-08-05 |
2022-08-03 |
GV
Geplanter Verkauf
|
Lotvin Alan
EVP&President-PharmacyServices
Führungsperson
|
50.501
-31.6%
98,00
4.949.098 USD
|
50.501
-31.6%
|
98,00
|
4.949.098 USD
|
|
|
2022-08-05 |
2022-08-03 |
GV
Geplanter Verkauf
|
Lotvin Alan
EVP&President-PharmacyServices
Führungsperson
|
70.398
-39.2%
98,00
6.899.004 USD
|
70.398
-39.2%
|
98,00
|
6.899.004 USD
|
|
|
2022-08-05 |
2022-08-03 |
GV
Geplanter Verkauf
|
Finke Daniel P
EVP/Pres, Health Care Benefits
Führungsperson
|
9.546
-22.9%
100,00
954.600 USD
|
9.546
-22.9%
|
100,00
|
954.600 USD
|
|
|
2022-04-12 |
2022-04-08 |
GV
Geplanter Verkauf
|
Shah Prem S
EVP and Co-President of Retail
Führungsperson
|
3.130
-6.7%
105,00
328.650 USD
|
3.130
-6.7%
|
105,00
|
328.650 USD
|
|
|
2022-04-12 |
2022-04-08 |
GV
Geplanter Verkauf
|
Shah Prem S
EVP and Co-President of Retail
Führungsperson
|
4.103
-8.1%
105,00
430.815 USD
|
4.103
-8.1%
|
105,00
|
430.815 USD
|
|
|
2022-04-12 |
2022-04-08 |
GV
Geplanter Verkauf
|
Shah Prem S
EVP and Co-President of Retail
Führungsperson
|
5.719
-10.9%
105,00
600.495 USD
|
5.719
-10.9%
|
105,00
|
600.495 USD
|
|
|
2022-04-12 |
2022-04-08 |
GV
Geplanter Verkauf
|
Shah Prem S
EVP and Co-President of Retail
Führungsperson
|
3.157
-6.3%
105,00
331.485 USD
|
3.157
-6.3%
|
105,00
|
331.485 USD
|
|
|
2022-04-12 |
2022-04-08 |
GV
Geplanter Verkauf
|
Shah Prem S
EVP and Co-President of Retail
Führungsperson
|
845
-1.8%
105,00
88.725 USD
|
845
-1.8%
|
105,00
|
88.725 USD
|
|
|
2022-04-06 |
2022-04-05 |
GV
Geplanter Verkauf
|
Finke Daniel P
EVP/Pres, Health Care Benefits
Führungsperson
|
5.941
-15.6%
100,00
594.100 USD
|
5.941
-15.6%
|
100,00
|
594.100 USD
|
|
|
2022-04-06 |
2022-04-04 |
GV
Geplanter Verkauf
|
Finke Daniel P
EVP/Pres, Health Care Benefits
Führungsperson
|
12.032
-24.0%
100,13
1.204.764 USD
|
12.032
-24.0%
|
100,13
|
1.204.764 USD
|
|
|
2022-04-06 |
2022-04-04 |
GV
Geplanter Verkauf
|
Finke Daniel P
EVP/Pres, Health Care Benefits
Führungsperson
|
27.166
-35.1%
100,13
2.720.132 USD
|
27.166
-35.1%
|
100,13
|
2.720.132 USD
|
|
|
2022-04-06 |
2022-04-04 |
GV
Geplanter Verkauf
|
Finke Daniel P
EVP/Pres, Health Care Benefits
Führungsperson
|
16.161
-24.4%
100,13
1.618.201 USD
|
16.161
-24.4%
|
100,13
|
1.618.201 USD
|
|
|
2022-03-18 |
2022-03-17 |
V
Verkauf
|
Shah Prem S
EVP and Co-President of Retail
Führungsperson
|
2.935
-4.7%
106,65
313.018 USD
|
2.935
-4.7%
|
106,65
|
313.018 USD
|
|
|
2022-03-18 |
2022-03-17 |
V
Verkauf
|
Shah Prem S
EVP and Co-President of Retail
Führungsperson
|
1.689
-2.8%
106,65
180.132 USD
|
1.689
-2.8%
|
106,65
|
180.132 USD
|
|
|
2022-03-17 |
2022-03-15 |
V
Verkauf
|
Moriarty Thomas M
EVP & General Counsel
Führungsperson
|
51.361
-5.8%
105,00
5.392.905 USD
|
51.361
-5.8%
|
105,00
|
5.392.905 USD
|
|
|
2022-02-11 |
2022-02-10 |
K
Kauf
|
LUDWIG EDWARD J
Nicht geschäftsführender Verwaltungsratsmitglied
|
1.000
+5.8%
105,90
105.904 USD
|
1.000
+5.8%
|
105,90
|
105.904 USD
|
|
|
2022-02-04 |
2022-02-03 |
GV
Geplanter Verkauf
|
Brennan Troyen A
EVP and Chief Medical Officer
Führungsperson
|
47.937
-25.7%
110,00
5.273.070 USD
|
47.937
-25.7%
|
110,00
|
5.273.070 USD
|
|
|
2022-02-02 |
2022-02-01 |
GV
Geplanter Verkauf
|
Lotvin Alan
EVP&President-PharmacyServices
Führungsperson
|
21.386
-25.9%
106,50
2.277.566 USD
|
21.386
-25.9%
|
106,50
|
2.277.566 USD
|
|
|
2022-02-01 |
2022-01-28 |
GV
Geplanter Verkauf
|
Clark James David
SVP, Cont & Chief Acct Officer
Führungsperson
|
6.059
-25.7%
109,00
660.431 USD
|
6.059
-25.7%
|
109,00
|
660.431 USD
|
|
|
2022-01-28 |
2022-01-27 |
GV
Geplanter Verkauf
|
Roberts Jonathan C
EVP & Chief Operating Officer
Führungsperson
|
68.482
-39.0%
107,50
7.361.815 USD
|
68.482
-39.0%
|
107,50
|
7.361.815 USD
|
|
|
2021-11-05 |
2021-11-03 |
GV
Geplanter Verkauf
|
Roberts Jonathan C
EVP & Chief Operating Officer
Führungsperson
|
108.870
-50.4%
95,00
10.342.650 USD
|
108.870
-50.4%
|
95,00
|
10.342.650 USD
|
|
|
2021-11-03 |
2021-11-01 |
V
Verkauf
|
Brennan Troyen A
EVP and Chief Medical Officer
Führungsperson
|
28.159
-16.9%
90,00
2.534.310 USD
|
28.159
-16.9%
|
90,00
|
2.534.310 USD
|
|
|
2021-10-28 |
2021-10-26 |
GV
Geplanter Verkauf
|
Brennan Troyen A
EVP and Chief Medical Officer
Führungsperson
|
80.802
-36.9%
88,00
7.110.576 USD
|
80.802
-36.9%
|
88,00
|
7.110.576 USD
|
|
|
2021-10-28 |
2021-10-26 |
V
Verkauf
|
Brennan Troyen A
EVP and Chief Medical Officer
Führungsperson
|
1.955
-0.9%
88,00
172.040 USD
|
1.955
-0.9%
|
88,00
|
172.040 USD
|
|
|
2021-06-29 |
2021-06-28 |
GV
Geplanter Verkauf
|
Lotvin Alan
EVP&President-PharmacyServices
Führungsperson
|
2.781
-4.4%
83,67
232.686 USD
|
2.781
-4.4%
|
83,67
|
232.686 USD
|
|
|
2021-06-17 |
2021-06-15 |
GV
Geplanter Verkauf
|
Brennan Troyen A
EVP and Chief Medical Officer
Führungsperson
|
67.552
-32.1%
86,00
5.809.472 USD
|
67.552
-32.1%
|
86,00
|
5.809.472 USD
|
|
|
2021-06-08 |
2021-06-07 |
GV
Geplanter Verkauf
|
Finke Daniel P
EVP/Pres, Health Care Benefits
Führungsperson
|
37.594
-61.7%
86,60
3.255.640 USD
|
37.594
-61.7%
|
86,60
|
3.255.640 USD
|
|
|
2021-05-12 |
2021-05-10 |
GV
Geplanter Verkauf
|
Moriarty Thomas M
EVP & General Counsel
Führungsperson
|
109.469
-100.0%
86,00
9.414.334 USD
|
109.469
-100.0%
|
86,00
|
9.414.334 USD
|
|
|
2021-05-10 |
2021-05-07 |
GV
Geplanter Verkauf
|
Brennan Troyen A
EVP and Chief Medical Officer
Führungsperson
|
9.477
-6.1%
84,00
796.068 USD
|
9.477
-6.1%
|
84,00
|
796.068 USD
|
|
|
2021-05-06 |
2021-05-04 |
GV
Geplanter Verkauf
|
Boratto Eva C
EVP & CFO
Führungsperson
|
4.905
-4.1%
80,00
392.400 USD
|
4.905
-4.1%
|
80,00
|
392.400 USD
|
|
|
2021-04-23 |
2021-04-21 |
GV
Geplanter Verkauf
|
Moriarty Thomas M
EVP & General Counsel
Führungsperson
|
2.420
-100.0%
77,00
186.340 USD
|
2.420
-100.0%
|
77,00
|
186.340 USD
|
|
|
2021-04-23 |
2021-04-21 |
GV
Geplanter Verkauf
|
Moriarty Thomas M
EVP & General Counsel
Führungsperson
|
101.003
-97.7%
77,00
7.777.231 USD
|
101.003
-97.7%
|
77,00
|
7.777.231 USD
|
|
|
2021-04-01 |
2021-03-31 |
GV
Geplanter Verkauf
|
Clark James David
SVP, Cont & Chief Acct Officer
Führungsperson
|
5.350
-42.5%
76,00
406.600 USD
|
5.350
-42.5%
|
76,00
|
406.600 USD
|
|
|
2021-03-30 |
2021-03-29 |
GV
Geplanter Verkauf
|
Moriarty Thomas M
EVP & General Counsel
Führungsperson
|
62.943
-100.0%
76,15
4.793.109 USD
|
62.943
-100.0%
|
76,15
|
4.793.109 USD
|
|
|
2021-03-29 |
2021-03-26 |
GV
Geplanter Verkauf
|
MERLO LARRY J
Nicht geschäftsführender Verwaltungsratsmitglied
|
270.650
-34.1%
74,73
20.225.675 USD
|
270.650
-34.1%
|
74,73
|
20.225.675 USD
|
|
|
2021-03-29 |
2021-03-26 |
GV
Geplanter Verkauf
|
Roberts Jonathan C
EVP & Chief Operating Officer
Führungsperson
|
73.433
-99.1%
74,49
5.470.024 USD
|
73.433
-99.1%
|
74,49
|
5.470.024 USD
|
|
|
2021-03-23 |
2021-03-19 |
GV
Geplanter Verkauf
|
Moriarty Thomas M
EVP & General Counsel
Führungsperson
|
49.211
-73.0%
74,15
3.648.996 USD
|
49.211
-73.0%
|
74,15
|
3.648.996 USD
|
|
|
2021-03-17 |
2021-03-16 |
GV
Geplanter Verkauf
|
Boratto Eva C
EVP & CFO
Führungsperson
|
18.882
-21.0%
74,68
1.410.108 USD
|
18.882
-21.0%
|
74,68
|
1.410.108 USD
|
|
|
2021-02-17 |
2021-02-17 |
K
Kauf
|
LUDWIG EDWARD J
Nicht geschäftsführender Verwaltungsratsmitglied
|
3.000
+26.5%
72,00
216.000 USD
|
3.000
+26.5%
|
72,00
|
216.000 USD
|
|
|
2021-01-21 |
2021-01-19 |
GV
Geplanter Verkauf
|
MERLO LARRY J
President and CEO
Geschäftsführender Verwaltungsratsmitglied
|
62.893
-10.7%
77,00
4.842.761 USD
|
62.893
-10.7%
|
77,00
|
4.842.761 USD
|
|
|
2021-01-13 |
2021-01-12 |
GV
Geplanter Verkauf
|
Bisaccia Lisa
EVP and Chief HR Officer
Führungsperson
|
25.177
-35.1%
77,00
1.938.629 USD
|
25.177
-35.1%
|
77,00
|
1.938.629 USD
|
|
|
2021-01-12 |
2021-01-08 |
GV
Geplanter Verkauf
|
Lotvin Alan
EVP and President-CVS Caremark
Führungsperson
|
25.836
-75.5%
75,00
1.937.700 USD
|
25.836
-75.5%
|
75,00
|
1.937.700 USD
|
|
|
2021-01-12 |
2021-01-08 |
GV
Geplanter Verkauf
|
Brennan Troyen A
EVP and Chief Medical Officer
Führungsperson
|
58.896
-56.1%
75,00
4.417.200 USD
|
58.896
-56.1%
|
75,00
|
4.417.200 USD
|
|
|
2020-11-17 |
2020-11-13 |
GV
Geplanter Verkauf
|
Lotvin Alan
EVP and President-CVS Caremark
Führungsperson
|
7.138
-47.1%
70,00
499.660 USD
|
7.138
-47.1%
|
70,00
|
499.660 USD
|
|
|
2020-11-12 |
2020-11-10 |
GV
Geplanter Verkauf
|
Flum Joshua Matthew
EVP, ENT STRATEGY & DIGITAL
Führungsperson
|
21.460
-46.2%
70,00
1.502.200 USD
|
21.460
-46.2%
|
70,00
|
1.502.200 USD
|
|
|
2020-05-28 |
2020-05-26 |
GV
Geplanter Verkauf
|
Clark James David
SVP, Cont & Chief Acct Officer
Führungsperson
|
270
-5.6%
65,00
17.550 USD
|
270
-5.6%
|
65,00
|
17.550 USD
|
|
|
2020-05-28 |
2020-05-26 |
GV
Geplanter Verkauf
|
Mayhew Jonathan E.
EVP - Transformation
Führungsperson
|
10.556
-69.0%
65,00
686.140 USD
|
10.556
-69.0%
|
65,00
|
686.140 USD
|
|
|
2020-05-13 |
2020-05-11 |
K
Kauf
|
Lotvin Alan
EVP and President-CVS Caremark
Führungsperson
|
5.000
+49.2%
63,14
315.675 USD
|
5.000
+49.2%
|
63,14
|
315.675 USD
|
|
|
2020-04-30 |
2020-04-28 |
GV
Geplanter Verkauf
|
Clark James David
SVP, Cont & Chief Acct Officer
Führungsperson
|
6.234
-56.4%
65,00
405.210 USD
|
6.234
-56.4%
|
65,00
|
405.210 USD
|
|
|
2020-04-01 |
2020-03-30 |
GV
Geplanter Verkauf
|
Clark James David
SVP, Cont & Chief Acct Officer
Führungsperson
|
3.030
-23.7%
60,00
181.800 USD
|
3.030
-23.7%
|
60,00
|
181.800 USD
|
|
|
2020-01-17 |
2020-01-15 |
GV
Geplanter Verkauf
|
MERLO LARRY J
President and CEO
Geschäftsführender Verwaltungsratsmitglied
|
266.476
-37.9%
74,79
19.929.740 USD
|
266.476
-37.9%
|
74,79
|
19.929.740 USD
|
|
|
2020-01-10 |
2020-01-08 |
GV
Geplanter Verkauf
|
Roberts Jonathan C
EVP & Chief Operating Officer
|
57.563
-56.1%
72,63
4.180.801 USD
|
57.563
-56.1%
|
72,63
|
4.180.801 USD
|
|
|
2019-11-20 |
2019-11-18 |
GV
Geplanter Verkauf
|
Lynch Karen S
EVP & Pres, Aetna Bus Unit
|
80.143
-65.7%
75,00
6.010.725 USD
|
80.143
-65.7%
|
75,00
|
6.010.725 USD
|
|
|
2019-11-06 |
2019-11-04 |
GV
Geplanter Verkauf
|
Brennan Troyen A
EVP and Chief Medical Officer
Führungsperson
|
23.604
-21.9%
68,00
1.605.072 USD
|
23.604
-21.9%
|
68,00
|
1.605.072 USD
|
|
|
2019-10-01 |
2019-09-30 |
GV
Geplanter Verkauf
|
Flum Joshua Matthew
EVP, ENT STRATEGY & DIGITAL
|
17.703
-49.0%
63,00
1.115.289 USD
|
17.703
-49.0%
|
63,00
|
1.115.289 USD
|
|
|
2019-09-13 |
2019-09-12 |
GV
Geplanter Verkauf
|
Boratto Eva C
EVP & CFO
|
8.130
-14.7%
65,00
528.450 USD
|
8.130
-14.7%
|
65,00
|
528.450 USD
|
|
|
2019-03-11 |
2019-03-11 |
K
Kauf
|
BROWN C DAVID II
|
10.000
+9.9%
53,18
531.800 USD
|
10.000
+9.9%
|
53,18
|
531.800 USD
|
|
|
2019-03-11 |
2019-03-11 |
K
Kauf
|
AGUIRRE FERNANDO
|
1.900
+13.3%
53,59
101.821 USD
|
1.900
+13.3%
|
53,59
|
101.821 USD
|
|
|
2019-03-11 |
2019-03-08 |
K
Kauf
|
LUDWIG EDWARD J
|
2.000
+37.2%
52,80
105.600 USD
|
2.000
+37.2%
|
52,80
|
105.600 USD
|
|
|
2019-03-11 |
2019-03-08 |
K
Kauf
|
DORMAN DAVID W
Nicht geschäftsführender Verwaltungsratsmitglied
|
9.600
+8.5%
52,71
506.016 USD
|
9.600
+8.5%
|
52,71
|
506.016 USD
|
|
|
2019-03-04 |
2019-03-01 |
K
Kauf
|
AGUIRRE FERNANDO
|
3.410
+31.2%
58,29
198.769 USD
|
3.410
+31.2%
|
58,29
|
198.769 USD
|
|
|
2019-03-04 |
2019-03-01 |
K
Kauf
|
LUDWIG EDWARD J
|
4.000
+290.3%
58,27
233.080 USD
|
4.000
+290.3%
|
58,27
|
233.080 USD
|
|
|
2019-03-01 |
2019-03-01 |
V
Verkauf
|
Clark James David
SVP, Cont & Chief Acct Officer
Führungsperson
|
1.664
-19.4%
58,14
96.745 USD
|
1.664
-19.4%
|
58,14
|
96.745 USD
|
|
